nivolumab
bms
['opdivo', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
opdivo doubled the average length of time without disease recurrence; the median disease-free survival was 22.0 months in the opdivo arm versus 10.9 months in patients on placebo #gu23 #ascogu23 #asco #asco23
#iPharmaCenter is a #website which covers #pharmaceutical and #healthcare #news plus #blogs #diseases #drugs #healthcaresystems #globalhealth #pharma